Evidence map›Paper›PMID 39924345›Full record

ArticleJournal of public health (Oxford, England)2025

The pre-exposure prophylaxis personal obstacle scale: measurement properties in English, German, and French.

Alexander Ort, Tess L C Bardy

Abstract read
In one paragraph

Article in Journal of public health (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Alexander OrtFaculty of Health Sciences and Medicine, University of Lucerne, Frohburgstrasse 3, CH-6002 Lucerne, Switzerland.ORCID 0000-0003-0112-9052
Tess L C BardyGroupe Mutuel Insurance, Rue des Cèdres 5, CH-1920, Martigny, Switzerland.ORCID 0000-0002-0071-3508

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to validate the Pre-Exposure Prophylaxis Personal Obstacle Scale (PPOS) across English, German, and French (PPOS-EN/DE/FR) for men who have sex with men (MSM). The PPOS measures perceived barriers related to knowledge and uncertainty surrounding PrEP use, which are particularly important factors in the early stages of the PrEP Care Continuum (PCC).

methodsThe original PPOS was adapted and translated into German and French. Data were collected through an online survey in four European countries (N = 1124). Exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) assessed the factor structure, while multigroup CFA (MGCFA) tested measurement invariance across language groups and adoption statuses.

resultsEFA revealed a two-factor structure: (i) "Impact of PrEP on personal health" and (ii) "Knowledge about PrEP." CFA confirmed this structure, and measurement invariance was established across languages and adoption statuses with high reliability (α = 0·82, ω = 0·82).

conclusionsThe PPOS-EN/DE/FR is a valid and reliable tool for assessing personal obstacles to PrEP uptake among MSM across different languages. It supports public health efforts by identifying specific challenges to PrEP adoption, facilitating culturally sensitive interventions to improve uptake and reduce HIV transmission.

Indexed as

Health Knowledge, Attitudes, PracticeHIV InfectionsHomosexuality, MalePre-Exposure ProphylaxisAdultEuropeFactor Analysis, StatisticalGermanyHumansLanguageMaleMiddle AgedReproducibility of ResultsSurveys and QuestionnairesYoung Adultcross-cultural measurementHIV preventionmen who have sex with menpersonal barrierspre-exposure prophylaxisscale validation

Identifiers

PMID39924345
PMCPMC12123318

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.